Refreshed just now
STAT+: Most-favored nations policy makes drugmakers rethink launches abroad
Why it’s here: The item is a newsletter-style roundup bundling several stories, but its lead concerns Trump's most-favored-nations drug pricing policy and its effect on launch decisions, which is a biotech federal policy issue.
Trace across the boardItem
10d agoSTATSTAT+: Most-favored nations policy makes drugmakers rethink launches abroadSTAT+ newsletter item flagging that most-favored-nation pricing policy is prompting drugmakers to reconsider foreign drug launches, alongside a whistleblower-style lawsuit against Eli Lilly over Mounjaro promotion.1 outlet1 linked
Connected
1 links- NewsSTAT+: Big drugmakers tell House committee they will halt clinical trials at some hospitals in ChinaBoth involve Eli Lilly